|
| 37470152 | Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. | Haematologica | 2024 |
| 36053786 | Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. | Blood Adv | 2023 |
| 37526512 | Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. | Leuk Lymphoma | 2023 |
| 37960985 | A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia. | Cancer Med | 2023 |
| 37801234 | Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients. | Adv Ther | 2023 |
| 37584447 | The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. | Am J Hematol | 2023 |
| 37648261 | Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. | J Immunother Cancer | 2023 |
| 37735756 | Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. | Clin Cancer Res | 2023 |
| 37682791 | Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. | Blood Adv | 2023 |
| 36958463 | Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. | Hum Pathol | 2023 |
| 37210271 | Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37005652 | Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. | Cardiooncology | 2023 |
| 36753699 | Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. | J Clin Oncol | 2023 |
| 36624015 | Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. | Clin Lymphoma Myeloma Leuk | 2023 |
| 36878427 | Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. | Transplant Cell Ther | 2023 |
| 36691748 | Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 36912764 | Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead. | Blood Adv | 2023 |
| 36627710 | Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. | J Exp Clin Cancer Res | 2023 |
| 35970303 | Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. | Transplant Cell Ther | 2023 |
| 36301721 | Frontline treatment approaches in <i>TP53</i>-aberrant mantle cell lymphoma. | Leuk Lymphoma | 2023 |
| 34343238 | Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. | Arch Pathol Lab Med | 2022 |
| 35378330 | Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. | Transplant Cell Ther | 2022 |
| 35580732 | Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. | Transplant Cell Ther | 2022 |
| 35727476 | Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. | Adv Ther | 2022 |
| 35816359 | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. | Blood Adv | 2022 |
| 36549782 | Dose-response correlation for CAR-T cells: a systematic review of clinical studies. | J Immunother Cancer | 2022 |
| 36494725 | Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. | J Hematol Oncol | 2022 |
| 36174934 | Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. | Transplant Cell Ther | 2022 |
| 35877996 | The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. | Blood | 2022 |
| 34162179 | Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. | Haematologica | 2022 |
| 34210750 | Association between ibrutinib treatment and hypertension. | Heart | 2022 |
| 32327504 | Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. | Haematologica | 2021 |
| 33827116 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. | Blood | 2021 |
| 33512407 | Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. | Blood | 2021 |
| 33641257 | Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. | Cancer Med | 2021 |
| 33730585 | Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. | Cell Rep | 2021 |
| 33781520 | Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. | Transplant Cell Ther | 2021 |
| 33634729 | Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. | J Med Econ | 2021 |
| 33798768 | Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. | Transplant Cell Ther | 2021 |
| 34551384 | Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 34188994 | COVID-19 Virus Infection in Three Patients With Hypogammaglobulinemia. | Cureus | 2021 |
| 34077811 | Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. | Transplant Cell Ther | 2021 |
| 34242714 | Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. | Int J Radiat Oncol Biol Phys | 2021 |
| 34097852 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. | Lancet | 2021 |
| 33458921 | First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. | Oncologist | 2021 |
| 33190829 | Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. | Biochem Biophys Res Commun | 2021 |
| 33446629 | MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. | Blood Cancer J | 2021 |
| 32950461 | Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. | Clin Lymphoma Myeloma Leuk | 2021 |
| 32496158 | Electrocardiographic Changes Associated With Ibrutinib Exposure. | Cancer Control | 2020 |
| 31636097 | Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. | Clin Cancer Res | 2020 |